For the reasons described in an earlier section of this text, accurate, reproducible lesion dosimetry is not yet possible. When the substantial technical issues around this measurement have been solved, the threshold dose below which pain relief rarely occurs can be determined. Then the information from a bone scan may be used to decide if administration of one of these radiopharmaceuticals will have any analgesic effect. With reliable marrow dosimetry, the nuclear medicine physician will also have a better idea of the degree of myelosuppression to expect. Currently, the clinician can only deal with these considerations empirically.
Was this article helpful?